🔍 As digitization grows, the sector is increasingly seen as critical infrastructure.
🔒 Researchers warn of vulnerabilities in quality control, regulatory compliance, and data protection.
🛡️ Enhanced interoperability and investment in IT are essential for safeguarding systems against cyber threats.
🤖 Innovators must prioritize security standards to prevent disruption in this vital industry.
Introduction:
The article discusses the critical importance of protecting the cell and gene therapy manufacturing sector against cyberattacks, as it increasingly relies on digital technologies for production. Researchers highlight the rising need for safeguarding these processes, which are regarded as vital infrastructure in society.
- Digitization enhances efficiency and traceability in cell and gene therapy manufacturing but also raises vulnerability to cyber threats.
- The sector is designated as “critical infrastructure,” necessitating heightened security measures to prevent supply chain disruptions.
- Three main challenges to safeguarding automated manufacturing include ensuring quality control, navigating regulatory compliance, and protecting sensitive data.
- Investment in IT expertise and robust manufacturing systems is essential for mitigating cyber risks.
- Improving interoperability among technology suppliers could reduce vulnerabilities related to system integration and data exchanges.
Conclusion:
The article emphasizes the urgency for the cell and gene therapy manufacturing sector to bolster its cybersecurity measures. Addressing the outlined challenges and improving system interoperability can significantly enhance the resilience of these critical infrastructures against potential cyberattacks, ensuring safe and consistent therapeutic production in the future.
